Contents of this document
- Economic conditions in major markets
- Supply and demand for products
- Raw Materials and Fuel Prices
- Interest Rates
- Foreign Exchange Rates
- Transition to a company-wide, cross-functional R&D structure led by the CTO
- Establishment of a European headquarters and development of a global management structure through regional headquarters
- Preparation for the listing of the Machinery and cement-related businesses on the Tokyo Stock Exchange
- Raising the DOE target to 3.5% or more, with an early goal of 4.0%
- Company-wide operational reform using generative AI and DX
- Scaling back or discontinuing production of ammonia, caprolactam and nylon polymer in Thailand and Japan
- EBITDA¥46.4 billion (FY2025 results)
- EBITDA margin10.0% (FY2025 results)
- ROS4.1% (FY2025 results)
- ROE5.7% (FY2025 results)
- ROIC3.8% (FY2025 results)
- Annual operational efficiency improvements41,000 hours
- Technical reportsMore than 7,000
- Global No. 1 share in polyimide varnish for flexible OLEDs
- World-leading share in ceramic bearing balls
- CAGR of 8% or more in the global pharmaceutical market over the next 7 years
- Market growth rates for urethane systems by application: approximately 1%-11%, depending on the application
| Item | Details |
|---|---|
| Document type | Medium-Term Management Plan Presentation |
| Fiscal Period Covered | FY2025 results and FY2026/FY2030 plans |
| Net Sales | ¥4,623 hundred million |
| Operating profit | ¥189 hundred million |
| Ordinary income | ¥375 hundred million |
| Net income | ¥239 hundred million |
| Operating profit margin | Rate 4.1% (FY2025 results) / Year-on-year change (points) Not disclosed |
| Full-year earnings forecast | Fiscal 2026 Net Sales ¥485.0 billion / EBITDA ¥56.5 billion / Operating profit ¥23.5 billion / Ordinary income ¥37.5 billion / Extraordinary Gains and Losses -¥4.0 billion / Profit attributable to owners of the parent ¥24.5 billion / FY2030 Net Sales ¥550 billion / EBITDA ¥115 billion / Operating profit ¥60 billion / Ordinary income ¥65.0 billion / Extraordinary Gains and Losses -¥5.5 billion / Restructuring Costs -¥5.5 billion / Profit attributable to owners of the parent ¥45 billion |
| Segment results | Functional products FY2025 revenue ¥71.0 billion / FY2025 operating profit ¥9.9 billion / High-performance urethane FY2025 revenue ¥46.5 billion / FY2025 operating profit -¥500 million / Pharmaceuticals FY2025 revenue ¥21.0 billion / FY2025 operating profit -¥1.3 billion / Resins and chemicals FY2025 revenue ¥248.8 billion / FY2025 operating profit ¥8 billion / Machinery FY2025 revenue ¥68.4 billion / FY2025 operating profit ¥6.2 billion / Other FY2025 revenue ¥34.5 billion / FY2025 operating profit ¥1.9 billion / Adjustments FY2025 revenue -¥27.9 billion / FY2025 operating profit -¥5.3 billion |
| Key KPIs | Indicator name EBITDA / Value ¥46.4 billion (FY2025 results) / Year on year against the same period last year Not disclosed, Indicator name EBITDA margin / Value 10.0% (FY2025 results) / Year on year against the same period last year Not disclosed, Indicator name ROS / Value 4.1% (FY2025 results) / Year on year against the same period last year Not disclosed, Indicator name ROE / Value 5.7% (FY2025 results) / Year on year against the same period last year Not disclosed, Indicator name ROIC / Value 3.8% (FY2025 results) / Year on year against the same period last year Not disclosed, Indicator name Annual operational efficiency improvements / Value 41,000 hours / Year on year against the same period last year Not disclosed, Indicator name Technical reports / Value More than 7,000 / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 1,683 employees, consolidated UBE Machinery Group (as of 1 April 2026) / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Economic conditions in major markets, Supply and demand for products, Raw Materials and Fuel Prices, Interest Rates, Foreign Exchange Rates |
| Medium-term management plan targets | Target fiscal year FY2030 / Net Sales ¥550 billion / EBITDA ¥100.0 billion or more (the plan value in the supplementary table is ¥115.0 billion) / Operating profit ¥60 billion / ROS 10% or more (the plan value in the supplementary table is 11.0%) / ROE 8% or more (the plan value in the supplementary table is 9.0%) / ROIC 6% or more (the plan value in the supplementary table is 7.0%) |
| Financial targets | Debt-to-equity ratio 0.58x (FY2030 target) / Equity ratio Not disclosed / ROE 9.0% (FY2030 target) / ROIC 7.0% (FY2030 target) / ROS 11.0% (FY2030 target) |
| Annual Dividend | Annual dividend per share ¥160 (forecast for the fiscal year ending March 2027) / Interim and Year-End Breakdown Not disclosed |
| Acquisition of treasury shares | Considering share repurchases using part of the IPO proceeds from the Machinery and cement-related businesses |
| Capital expenditures | ¥3,250 100 million (six-year medium-term management plan) |
| Market Size / Share | Global No. 1 share in polyimide varnish for flexible OLEDs, World-leading share in ceramic bearing balls, CAGR of 8% or more in the global pharmaceutical market over the next 7 years, Market growth rates for urethane systems by application: approximately 1%-11%, depending on the application |
| New initiatives | Transition to a company-wide, cross-functional R&D structure led by the CTO, Establishment of a European headquarters and development of a global management structure through regional headquarters, Preparation for the listing of the Machinery and cement-related businesses on the Tokyo Stock Exchange, Raising the DOE target to 3.5% or more, with an early goal of 4.0%, Company-wide operational reform using generative AI and DX, Scaling back or discontinuing production of ammonia, caprolactam and nylon polymer in Thailand and Japan |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In light of major investment projects entering the recovery phase, the company aims to maintain and improve capital efficiency and strengthen shareholder returns while continuing to invest in specialty businesses. It also aims to stabilize earnings and cash flow by shifting from basic businesses that depend on market conditions to high-margin, stable specialty businesses.